ArticleAmerican journal of translational research2023
miR-379-5p regulates the proliferation, cell cycle, and cisplatin resistance of oral squamous cell carcinoma cells by targeting ROR1.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 5 citations in OpenAlex.
- Transcriptomic Profiling of MicroRNA and Non-Coding RNA from Whole Blood of African Americans with MASLD.International journal of molecular sciences · 2026Article
- miR-379-5p promotes ovarian granulosa cell apoptosis in primary ovarian insufficiency by targeting KNDC1 and PEG10.Frontiers in genetics · 2026Article
- Non-Invasive Techniques for Early Detection of Oral Squamous Cell Carcinoma: A Narrative Review.Cancer management and research · 2026Review
- Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC.Drug discovery today · 2025Review
- Expression Analysis of miR-519a-3p and miR-379-5p in Colorectal Cancer Patients: A Combined Experimental and Bioinformatic Approach.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- miR-379-5p Inhibited the Proliferation of Acute Myeloid Leukemia Cells Through Negative Regulation ofTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- miR-379-5p affects breast cancer cell behavior by targeting UBE2E3 ubiquitin conjugating enzyme.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the regulatory mechanism microRNA miR-379-5p in oral squamous cell carcinoma (OSCC).
methodsWe collected serum samples from patients with OSCC and examined the expression of miR-379-5p and receptor tyrosine kinase-like orphan receptor 1 (ROR1) by real-time polymerase chain reaction and western blot. OSCC cells were purchased for molecular research, cell multiplication was tested using the BrdU assay, cell cycle was tested using flow cytometry, and resistance to cisplatin (DDP) was assessed using the MTT assay.
resultsmiR-379-5p expression was downregulated and ROR1 expression was upregulated in the serum of OSCC patients, and the area under the curve for OSCC identified by miR-379-5p and ROR1 was not less than 0.800. In the cell function test, overexpression of miR-379-5p could suppress the proliferation, cell cycle, and DDP resistance of OSCC cells. miR-379-5p could negatively regulate ROR1. Inhibition of ROR1 expression had a similar effect after the re-expression of miR-379-5p. Co-overexpression of miR-379-5p and ROR1 counteracted the above inhibitory effects on the proliferation, cell cycle, and DDP resistance of OSCC cells.
conclusionmiR-379-5p in OSCC regulates the proliferation, cell cycle, and DDP resistance of tumor cells by targeting ROR1.
Indexed as
Identifiers
37056860PMC10086902W4365483574What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.